Biocure Technology

Biocure Technology FCF/Debt

The Free Cash Flow to Debt Ratio of Biocure Technology (CURE.X.CN) as of Oct 18, 2026 is 27.62 %. In the previous year, Free Cash Flow to Debt Ratio was -518.14 % — a change of -105.33% (higher).

FCF/Debt

27.62 %

YoY

-105.33%

Last updated:

Free Cash Flow to Debt Ratio of Biocure Technology is 2024 27.62 % . Free Cash Flow to Debt Ratio of Biocure Technology was 2023 -518.14 % . It decreases by -105.33% higher compared to the previous year.

The Biocure Technology FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2020
-32.90 CAD
Jan 1, 2021
-28.59 CAD
Jan 1, 2022
-1,016.63 CAD
Jan 1, 2023
-518.14 CAD
Jan 1, 2024
27.62 CAD
The Biocure Technology FCF/Debt history
YEARFCF/DebtYoY
27.62 %-105.33%
-518.14 %-49.03%
-1,016.63 %+3,456.13%
-28.59 %-13.11%
-32.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocure Technology Stock analysis

What does Biocure Technology do? Biocure Technology Inc is a biotechnology company based in Vancouver, Canada, operating within the health care sector. The company went public on March 27, 2008, with the ticker CURE.X.CN and ISIN CA09075T2065. Its primary focus involves the development and commercialization of biosimilar products. Biocure Technology Inc is engaged in the development of biopharmaceutical technologies, including recombinant and ranibizumab-related applications. The company's product portfolio includes Interferon Beta, Ranibizumab, and PEG-Filgrastim. While the source description mentions CAR T-cell therapy targeting Chronic lymphocytic leukemia and solid tumor cancers, this information is not confirmed by the provided facts and is excluded. Similarly, the company's involvement in biosimilar technologies for cancer treatment is noted but not elaborated with specific details. Biocure Technology Inc's website is https://biocuretech.com/, where further information can be found. The company operates as a public entity with a presence in the biotechnology industry, focusing on innovative therapeutic solutions. No additional details regarding founding year, key personnel, acquisitions, or specific financial figures are provided in the available information. Biocure Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocure Technology stock

Free Cash Flow to Debt Ratio of Biocure Technology is 27.62 % in 2024.

Free Cash Flow to Debt Ratio of Biocure Technology changed from -518.14 % to 27.62 %, representing a -105.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Biocure Technology since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Biocure Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biocure Technology

All Key Metrics — Biocure Technology